NR3C2 and diabetic kidney disease: Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), improved kidney outcomes in patients with DKD (the FIDELIO-DKD trial [50], and an ongoing study tests CV outcome (The FIGARO-DKD trial, NCT02545049).